In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation

Tsutomu Watanabe, Linda S. Kelsey, Yun Yan, Gregory S. Brown, John D. Jackson, Cynthia Ewel, James E Talmadge

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We report that acetyl-N-Ser-Asp-Lys-Pro (AcSDKP), which removes progenitor cells from cell cycle, in combination with granulocyte-colony stimulating factor (G-CSF) can significantly improve myelorestoration following irradiation (7 Gy). Peripheral blood, spleen and bone marrow (BM) cell recovery and progenitor cell reconstitution [IL-3-responsive colony-forming cells (CFC) and high proliferative potential colony-forming cells (HPP-CFC)] were studied. Studies on the optimal schedule of AcSDKP administration revealed maximal effects on progenitor cells when AcSDKP was administered as a continuous infusion for 3 d starting 24 h prior to irradiation and used in combination with G-CSF. The numbers of CFC and HPP-CFC in the BM were significantly increased following irradiation in mice receiving AcSDKP and G-CSF as compared to either drug alone. The numbers of CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on days 10 and 14 as compared to AcSDKP alone, but not G-CSF. Similarly, CFC and HPP-CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on day 18 as compared to mice receiving PBS and G-CSF. These studies suggest that AcSDKP in combination with G-CSF may have potential for the protection of progenitor cells in patients undergoing intensive chemo- and/or radiotherapy.

Original languageEnglish (US)
Pages (from-to)619-627
Number of pages9
JournalBritish Journal of Haematology
Volume94
Issue number4
DOIs
StatePublished - Jan 1 1996

Fingerprint

Granulocyte Colony-Stimulating Factor
Stem Cells
Spleen
Bone Marrow Cells
goralatide
Interleukin-3
Appointments and Schedules
Cell Cycle
Radiotherapy

Keywords

  • AcSDKP
  • G-CSF
  • Haemoprotective
  • Progenitor cells
  • Sublethal irradiation

ASJC Scopus subject areas

  • Hematology

Cite this

In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation. / Watanabe, Tsutomu; Kelsey, Linda S.; Yan, Yun; Brown, Gregory S.; Jackson, John D.; Ewel, Cynthia; Talmadge, James E.

In: British Journal of Haematology, Vol. 94, No. 4, 01.01.1996, p. 619-627.

Research output: Contribution to journalArticle

Watanabe, Tsutomu ; Kelsey, Linda S. ; Yan, Yun ; Brown, Gregory S. ; Jackson, John D. ; Ewel, Cynthia ; Talmadge, James E. / In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation. In: British Journal of Haematology. 1996 ; Vol. 94, No. 4. pp. 619-627.
@article{95b82b6cf4c24ca6961536d2ac4f6ec7,
title = "In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation",
abstract = "We report that acetyl-N-Ser-Asp-Lys-Pro (AcSDKP), which removes progenitor cells from cell cycle, in combination with granulocyte-colony stimulating factor (G-CSF) can significantly improve myelorestoration following irradiation (7 Gy). Peripheral blood, spleen and bone marrow (BM) cell recovery and progenitor cell reconstitution [IL-3-responsive colony-forming cells (CFC) and high proliferative potential colony-forming cells (HPP-CFC)] were studied. Studies on the optimal schedule of AcSDKP administration revealed maximal effects on progenitor cells when AcSDKP was administered as a continuous infusion for 3 d starting 24 h prior to irradiation and used in combination with G-CSF. The numbers of CFC and HPP-CFC in the BM were significantly increased following irradiation in mice receiving AcSDKP and G-CSF as compared to either drug alone. The numbers of CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on days 10 and 14 as compared to AcSDKP alone, but not G-CSF. Similarly, CFC and HPP-CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on day 18 as compared to mice receiving PBS and G-CSF. These studies suggest that AcSDKP in combination with G-CSF may have potential for the protection of progenitor cells in patients undergoing intensive chemo- and/or radiotherapy.",
keywords = "AcSDKP, G-CSF, Haemoprotective, Progenitor cells, Sublethal irradiation",
author = "Tsutomu Watanabe and Kelsey, {Linda S.} and Yun Yan and Brown, {Gregory S.} and Jackson, {John D.} and Cynthia Ewel and Talmadge, {James E}",
year = "1996",
month = "1",
day = "1",
doi = "10.1046/j.1365-2141.1996.d01-1853.x",
language = "English (US)",
volume = "94",
pages = "619--627",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation

AU - Watanabe, Tsutomu

AU - Kelsey, Linda S.

AU - Yan, Yun

AU - Brown, Gregory S.

AU - Jackson, John D.

AU - Ewel, Cynthia

AU - Talmadge, James E

PY - 1996/1/1

Y1 - 1996/1/1

N2 - We report that acetyl-N-Ser-Asp-Lys-Pro (AcSDKP), which removes progenitor cells from cell cycle, in combination with granulocyte-colony stimulating factor (G-CSF) can significantly improve myelorestoration following irradiation (7 Gy). Peripheral blood, spleen and bone marrow (BM) cell recovery and progenitor cell reconstitution [IL-3-responsive colony-forming cells (CFC) and high proliferative potential colony-forming cells (HPP-CFC)] were studied. Studies on the optimal schedule of AcSDKP administration revealed maximal effects on progenitor cells when AcSDKP was administered as a continuous infusion for 3 d starting 24 h prior to irradiation and used in combination with G-CSF. The numbers of CFC and HPP-CFC in the BM were significantly increased following irradiation in mice receiving AcSDKP and G-CSF as compared to either drug alone. The numbers of CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on days 10 and 14 as compared to AcSDKP alone, but not G-CSF. Similarly, CFC and HPP-CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on day 18 as compared to mice receiving PBS and G-CSF. These studies suggest that AcSDKP in combination with G-CSF may have potential for the protection of progenitor cells in patients undergoing intensive chemo- and/or radiotherapy.

AB - We report that acetyl-N-Ser-Asp-Lys-Pro (AcSDKP), which removes progenitor cells from cell cycle, in combination with granulocyte-colony stimulating factor (G-CSF) can significantly improve myelorestoration following irradiation (7 Gy). Peripheral blood, spleen and bone marrow (BM) cell recovery and progenitor cell reconstitution [IL-3-responsive colony-forming cells (CFC) and high proliferative potential colony-forming cells (HPP-CFC)] were studied. Studies on the optimal schedule of AcSDKP administration revealed maximal effects on progenitor cells when AcSDKP was administered as a continuous infusion for 3 d starting 24 h prior to irradiation and used in combination with G-CSF. The numbers of CFC and HPP-CFC in the BM were significantly increased following irradiation in mice receiving AcSDKP and G-CSF as compared to either drug alone. The numbers of CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on days 10 and 14 as compared to AcSDKP alone, but not G-CSF. Similarly, CFC and HPP-CFC in the spleen were significantly increased in mice receiving AcSDKP and G-CSF on day 18 as compared to mice receiving PBS and G-CSF. These studies suggest that AcSDKP in combination with G-CSF may have potential for the protection of progenitor cells in patients undergoing intensive chemo- and/or radiotherapy.

KW - AcSDKP

KW - G-CSF

KW - Haemoprotective

KW - Progenitor cells

KW - Sublethal irradiation

UR - http://www.scopus.com/inward/record.url?scp=0029758395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029758395&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1996.d01-1853.x

DO - 10.1046/j.1365-2141.1996.d01-1853.x

M3 - Article

C2 - 8826883

AN - SCOPUS:0029758395

VL - 94

SP - 619

EP - 627

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -